Exelixis, Inc.
NASDAQ:EXELBiotechnology
+$0.34 today
- Market cap
- $17.17B
- Beta
- 0.43
- P/E (TTM)
- 16.3
- EPS (TTM)
- $3.23
Volume 1.82M
Average 2.55M
EXEL Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Exelixis, Inc.NASDAQ: EXEL
Gross Margin · Q2 FY2026 · quarter ended Jul 2026
Gross margin holds steady near 96.7%
Gross margin was 96.7% in Q2 FY2026, up 0.1 pp from a year earlier. On a trailing-twelve-month basis it was 96.5%, down 0.1 pp year over year. Over 3 fiscal years it narrowed by 0.0 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 96.4%
- Year-over-year change
- -0.1pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-02 | 96.4% | -0.1pp |
| FY2024 | 2025-01-03 | 96.5% | +0.4pp |
| FY2023 | 2023-12-31 | 96.0% | -0.4pp |
| FY2022 | 2022-12-31 | 96.4% | +0.1pp |
| FY2021 | 2021-12-31 | 96.3% | — |
Gross Margin vs competitors
How EXEL compares with its peers on the latest reported figures
- EXEL's LTM Jul 2026 gross margin of 96.5% is the 2nd highest of the 7 companies compared; the peer median is 92.8%.
- Its year-over-year change of -0.1 pp is the 3rd highest of 6, against a peer median of -0.3 pp.
- Over three fiscal years its change of -0.0 pp compares with a peer median of -1.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 98.0% | -0.0 pp | — | |
| LTM Jul 2026 | 96.5% | -0.1 pp | -0.0 pp | |
| LTM Mar 2026 | 93.4% | +3.7 pp | -5.2 pp | |
| LTM Jun 2026 | 93.0% | — | -8.3 pp | |
| LTM Jun 2026 | 92.6% | -0.3 pp | -1.1 pp | |
| LTM Sep 2026 | 80.1% | -2.3 pp | +9.8 pp | |
| LTM Jun 2025 | 8.9% | -20.9 pp | +11.6 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding EXEL) | 92.8% | -0.3 pp | -1.1 pp | |
Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.61B | 1.83B | 2.17B | 2.32B |
| Cost of Revenue | 52.87M | 57.91M | 72.55M | 76.22M | 83.7M |
| Gross Profit | 1.38B | 1.55B | 1.76B | 2.09B | 2.24B |
| Gross Margin | 96.3% | 96.4% | 96.0% | 96.5% | 96.4% |
| Research & Development | 693.72M | 891.81M | 1.04B | 910.41M | 825M |
| Selling, General & Admin | 401.72M | 459.86M | 542.71M | 492.13M | 518.73M |
| Operating Expenses | 1.1B | 1.35B | 1.59B | 1.49B | 1.36B |
| Depreciation & Amortization | 13.63M | 20.88M | 25.72M | 28.8M | 29.06M |
| EBITDA | 307.78M | 255.23M | 283.24M | 718.75M | 921.76M |
| EBITDA Margin | 21.4% | 15.8% | 15.5% | 33.1% | 39.7% |
| Operating Income | 286.67M | 201.48M | 170.89M | 604.62M | 872.19M |
| Operating Margin | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| Interest Income | 7.67M | 33.07M | 86.54M | 77.16M | 69.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 7.49M | 32.87M | 86.64M | 77.02M | 69.02M |
| Income Before Tax | 294.15M | 234.35M | 257.52M | 681.64M | 941.21M |
| Pre-Tax Margin | 20.5% | 14.5% | 14.1% | 31.4% | 40.6% |
| Income Tax Expense | 63.09M | 52.07M | 49.76M | 160.37M | 158.64M |
| Net Income | 231.06M | 182.28M | 207.77M | 521.27M | 782.57M |
| Net Margin | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
| EPS (Basic) | 0.73 | 0.57 | 0.65 | 1.80 | 2.88 |
| EPS (Diluted) | 0.72 | 0.56 | 0.65 | 1.76 | 2.78 |
| Weighted Avg Shares | 314.88M | 321.53M | 318.15M | 290.03M | 271.57M |
| Weighted Avg Shares (Diluted) | 322.36M | 324.56M | 321.46M | 296.13M | 281.86M |
Exelixis, Inc.
NASDAQ:EXEL
Intrinsic Alpha fair value
Locked
Current Price
$68.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.